{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T07:27:04Z","timestamp":1783495624887,"version":"3.55.0"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,1,22]],"date-time":"2021-01-22T00:00:00Z","timestamp":1611273600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001934","name":"American Academy of Dermatology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001934","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007707","name":"University of California, Davis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007707","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jaadinternational.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JAAD International"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.jdin.2021.01.002","type":"journal-article","created":{"date-parts":[[2021,3,12]],"date-time":"2021-03-12T07:26:30Z","timestamp":1615533990000},"page":"26-41","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Topical treatments for early-stage mycosis fungoides using Grading Recommendations Assessment, Development and Evaluation (GRADE) criteria: A systematic review"],"prefix":"10.1016","volume":"3","author":[{"given":"Ebba","family":"Wennberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillip Q.","family":"Richards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul A.","family":"Bain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sydney D.","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanual M.","family":"Maverakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel E.","family":"Molina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peggy A.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.jdin.2021.01.002_bib1","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1182\/blood-2007-03-055749","volume":"110","author":"Olsen","year":"2007","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.jdin.2021.01.002_bib2","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1001\/archderm.139.7.857","article-title":"Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression","volume":"139","author":"Kim","year":"2003","journal-title":"Arch Dermatol"},{"issue":"23","key":"10.1016\/j.jdin.2021.01.002_bib3","doi-asserted-by":"crossref","first-page":"5830","DOI":"10.1002\/cncr.27627","article-title":"Time course, clinical pathways, and long-term hazards risk trends of disease progression in patients with classic mycosis fungoides: a multicenter, retrospective follow-up study from the Italian Group of Cutaneous Lymphomas","volume":"118","author":"Quaglino","year":"2012","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.jdin.2021.01.002_bib4","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.jaad.2018.07.040","article-title":"Local radiation and phototherapy are the most cost-effective treatments for stage IA mycosis fungoides: a comparative decision analysis model in the United States","volume":"80","author":"Xia","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.jdin.2021.01.002_bib5","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/bjd.17240","article-title":"British Association of Dermatologists and U.K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous lymphomas 2018","volume":"180","author":"Gilson","year":"2019","journal-title":"Br J Dermatol"},{"issue":"Suppl 4","key":"10.1016\/j.jdin.2021.01.002_bib6","doi-asserted-by":"crossref","first-page":"iv30","DOI":"10.1093\/annonc\/mdy133","article-title":"Primary cutaneous lymphomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Willemze","year":"2018","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.jdin.2021.01.002_bib7","doi-asserted-by":"crossref","first-page":"3768","DOI":"10.1182\/blood-2004-09-3502","article-title":"WHO-EORTC classification for cutaneous lymphomas","volume":"105","author":"Willemze","year":"2005","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.jdin.2021.01.002_bib9","doi-asserted-by":"crossref","first-page":"223.e1","DOI":"10.1016\/j.jaad.2013.08.033","article-title":"Primary cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome): part II. Prognosis, management, and future directions","volume":"70","author":"Jawed","year":"2014","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.jdin.2021.01.002_bib10","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1111\/bjd.19252","article-title":"Treatment of early-stage mycosis fungoides: results from the PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study","volume":"184","author":"Quaglino","year":"2021","journal-title":"Br J Dermatol"},{"issue":"7","key":"10.1016\/j.jdin.2021.01.002_bib11","first-page":"CD008946","article-title":"Interventions for mycosis fungoides","volume":"7","author":"Valipour","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"issue":"9","key":"10.1016\/j.jdin.2021.01.002_bib12","first-page":"4","article-title":"Mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL) epidemiology and treatment pathway in Spain: new insights for an accurate description","volume":"2020","author":"D'Agostino","year":"2020","journal-title":"Drugs Context"},{"issue":"8","key":"10.1016\/j.jdin.2021.01.002_bib13","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1080\/09546634.2018.1466026","article-title":"Healthcare resource utilization, costs of care, and treatment of mycosis fungoides cutaneous T-cell lymphoma patterns in a large managed care population: a retrospective US claims-based analysis","volume":"29","author":"Tsang","year":"2018","journal-title":"J Dermatolog Treat"},{"issue":"1","key":"10.1016\/j.jdin.2021.01.002_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2046-4053-4-1","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement","volume":"4","author":"Moher","year":"2015","journal-title":"Syst Rev"},{"key":"10.1016\/j.jdin.2021.01.002_bib15","series-title":"Cochrane Handbook for Systematic Reviews of Interventions version 6.1","year":"2020"},{"key":"10.1016\/j.jdin.2021.01.002_bib16","series-title":"GRADE Handbook for Grading Quality of Evidence and Strength of Recommendations","author":"Sch\u00fcnemann","year":"2013"},{"issue":"7650","key":"10.1016\/j.jdin.2021.01.002_bib17","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.jdin.2021.01.002_bib18","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/j.jaad.2019.12.070","article-title":"Real-world experience with mechlorethamine gel in patients with mycosis fungoides-cutaneous lymphoma: preliminary findings from a prospective observational study","volume":"83","author":"Kim","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.jdin.2021.01.002_bib19","first-page":"79","article-title":"Mechlorethamine in the treatment of cutaneous T-cell lymphomas","volume":"5","author":"Ferreira","year":"1990","journal-title":"Skin Cancer"},{"issue":"5","key":"10.1016\/j.jdin.2021.01.002_bib20","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1046\/j.1365-2133.2002.04802.x","article-title":"Evaluation of a 1-h exposure time to mechlorethamine in patients undergoing topical treatment","volume":"147","author":"Foulc","year":"2002","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.jdin.2021.01.002_bib21","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1001\/archderm.1982.01650150012011","article-title":"Treatment of mycosis fungoides: total-skin electron-beam irradiation vs topical mechlorethamine therapy","volume":"118","author":"Hamminga","year":"1982","journal-title":"Arch Dermatol"},{"issue":"2","key":"10.1016\/j.jdin.2021.01.002_bib22","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1001\/archderm.139.2.165","article-title":"Topical nitrogen mustard in the management of mycosis fungoides: update of the Stanford experience","volume":"139","author":"Kim","year":"2003","journal-title":"Arch Dermatol"},{"issue":"1","key":"10.1016\/j.jdin.2021.01.002_bib23","first-page":"151","article-title":"Retrospective analysis of electron-beam vs topical nitrogen-mustard treatment in 248 patients with mycosis fungoides","volume":"87","author":"Lamberg","year":"1986","journal-title":"J Invest Dermatol"},{"issue":"1","key":"10.1016\/j.jdin.2021.01.002_bib24","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1001\/2013.jamadermatol.541","article-title":"Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides","volume":"149","author":"Lessin","year":"2013","journal-title":"JAMA Dermatol"},{"issue":"2","key":"10.1016\/j.jdin.2021.01.002_bib25","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/j.1468-3083.2011.04433.x","article-title":"Topical nitrogen mustard therapy in patients with mycosis fungoides or parapsoriasis","volume":"27","author":"Lindahl","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"10.1016\/j.jdin.2021.01.002_bib26","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/S0190-9622(88)70223-6","article-title":"Topical mechlorethamine therapy for early stage mycosis fungoides","volume":"19","author":"Ramsay","year":"1988","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.jdin.2021.01.002_bib27","first-page":"133","article-title":"Hypopigmented mycosis fungoides: a report of 7 cases and review of the literature","volume":"67","author":"Stone","year":"2001","journal-title":"Cutis"},{"issue":"4","key":"10.1016\/j.jdin.2021.01.002_bib28","first-page":"709","article-title":"Scandinavian mycosis fungoides trial","volume":"63","author":"Thomsen","year":"1979","journal-title":"Cancer Treat Rep"},{"issue":"3","key":"10.1016\/j.jdin.2021.01.002_bib29","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/S0190-9622(89)70051-7","article-title":"Long-term efficacy, curative potential, and carcinogenicity of topical mechlorethamine chemotherapy in cutaneous T cell lymphoma","volume":"20","author":"Vonderheid","year":"1989","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"10.1016\/j.jdin.2021.01.002_bib30","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1001\/archderm.141.9.1117","article-title":"Treatment of early-stage mycosis fungoides with twice-weekly applications of mechlorethamine and topical corticosteroids: a prospective study","volume":"141","author":"de Quatrebarbes","year":"2005","journal-title":"Arch Dermatol"},{"issue":"3","key":"10.1016\/j.jdin.2021.01.002_bib31","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1001\/archderm.138.3.325","article-title":"Phase 1 and 2 trial of bexarotene gel for skin-directed treatment of patients with cutaneous T-cell lymphoma","volume":"138","author":"Breneman","year":"2002","journal-title":"Arch Dermatol"},{"issue":"5","key":"10.1016\/j.jdin.2021.01.002_bib32","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/S0190-9622(03)01475-0","article-title":"Topical bexarotene therapy for patients with refractory or persistent early-stage cutaneous T-cell lymphoma: results of the phase III clinical trial","volume":"49","author":"Heald","year":"2003","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.jdin.2021.01.002_bib33","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.jaad.2003.09.005","article-title":"Tazarotene 0.1% gel for refractory mycosis fungoides lesions: an open-label pilot study","volume":"50","author":"Apisarnthanarax","year":"2004","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.jdin.2021.01.002_bib34","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1177\/1203475415626686","article-title":"Tazarotene 0.1% cream as monotherapy for early-stage cutaneous T-cell lymphoma","volume":"20","author":"Besner Morin","year":"2016","journal-title":"J Cutan Med Surg"},{"issue":"3","key":"10.1016\/j.jdin.2021.01.002_bib35","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.jaad.2020.05.043","article-title":"Response to topical corticosteroid monotherapy in mycosis fungoides","volume":"84","author":"Kartan","year":"2021","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"10.1016\/j.jdin.2021.01.002_bib36","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1001\/archderm.134.8.949","article-title":"Topical corticosteroids for mycosis fungoides. Experience in 79 patients","volume":"134","author":"Zackheim","year":"1998","journal-title":"Arch Dermatol"},{"issue":"5 Pt 1","key":"10.1016\/j.jdin.2021.01.002_bib37","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/0190-9622(90)70112-U","article-title":"Topical carmustine (BCNU) for cutaneous T cell lymphoma: a 15-year experience in 143 patients","volume":"22","author":"Zackheim","year":"1990","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"10.1016\/j.jdin.2021.01.002_bib38","first-page":"1017","article-title":"Six patients with early-stage cutaneous T-cell lymphoma successfully treated with topical 5-fluorouracil","volume":"9","author":"Kannangara","year":"2010","journal-title":"J Drugs Dermatol"},{"issue":"5","key":"10.1016\/j.jdin.2021.01.002_bib39","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1001\/archderm.139.5.624","article-title":"Phase 1\/2 pilot study of methotrexate-laurocapram topical gel for the treatment of patients with early-stage mycosis fungoides","volume":"139","author":"Demierre","year":"2003","journal-title":"Arch Dermatol"},{"issue":"6","key":"10.1016\/j.jdin.2021.01.002_bib40","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/0190-9622(93)70275-X","article-title":"Topical administration of hexadecylphosphocholine in patients with cutaneous lymphomas: results of a phase I\/II study","volume":"29","author":"Dummer","year":"1993","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.jdin.2021.01.002_bib41","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1067\/mjd.2001.113478","article-title":"A phase III, randomized, double-blind, placebo-controlled study of peldesine (BCX-34) cream as topical therapy for cutaneous T-cell lymphoma","volume":"44","author":"Duvic","year":"2001","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jdin.2021.01.002_bib42","doi-asserted-by":"crossref","first-page":"98","DOI":"10.2174\/1874372201711010098","article-title":"Prospective pilot evaluation of the efficacy and safety of topical ingenol mebutate gel for localized patch\/plaque stage mycosis fungoides","volume":"11","author":"Lebas","year":"2017","journal-title":"Open Dermatol J"},{"issue":"3","key":"10.1016\/j.jdin.2021.01.002_bib43","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.jid.2019.08.443","article-title":"Exploratory assessment of oxygen flow-assisted cutaneous administration of methotrexate for superficial basal cell carcinoma, mycosis fungoides, and extramammary Paget disease","volume":"140","author":"Lebas","year":"2020","journal-title":"J Invest Dermatol"},{"issue":"12","key":"10.1016\/j.jdin.2021.01.002_bib44","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1182\/blood-2015-02-630335","article-title":"Topical resiquimod can induce disease regression and enhance T-cell effector functions in cutaneous T-cell lymphoma","volume":"126","author":"Rook","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jdin.2021.01.002_bib45","series-title":"Risks of Picato for actinic keratosis outweigh benefits","year":"2020"},{"key":"10.1016\/j.jdin.2021.01.002_bib46","doi-asserted-by":"crossref","first-page":"260","DOI":"10.3389\/fonc.2019.00260","article-title":"Skin directed therapy in cutaneous T-cell lymphoma","volume":"9","author":"Tarabadkar","year":"2019","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.jdin.2021.01.002_bib47","doi-asserted-by":"crossref","first-page":"7","DOI":"10.21037\/cco.2018.11.03","article-title":"Update on skin directed therapies in mycosis fungoides","volume":"8","author":"Lovgren","year":"2019","journal-title":"Chin Clin Oncol"}],"container-title":["JAAD International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266632872100002X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266632872100002X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T20:58:09Z","timestamp":1762981089000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S266632872100002X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":46,"alternative-id":["S266632872100002X"],"URL":"https:\/\/doi.org\/10.1016\/j.jdin.2021.01.002","relation":{},"ISSN":["2666-3287"],"issn-type":[{"value":"2666-3287","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Topical treatments for early-stage mycosis fungoides using Grading Recommendations Assessment, Development and Evaluation (GRADE) criteria: A systematic review","name":"articletitle","label":"Article Title"},{"value":"JAAD International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdin.2021.01.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 by the American Academy of Dermatology, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}